Skip to main content
. 2008 Jul;57(7):1774–1783. doi: 10.2337/db07-1769

FIG. 4.

FIG. 4.

Potential sites at which individual PKC isoforms might be beneficially targeted for the treatment of type 2 diabetes. Inhibition of PKCɛ is predicted to improve insulin availability by restoring defective GSIS and by diminishing hepatic insulin clearance. This may also improve insulin sensitivity in liver and muscle. Targeting PKCδ may be of benefit in maintaining β-cell mass and in treating insulin resistance in muscle and liver. See text for details.